U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047989) titled 'NWRD09 for HPV-16 Related Cervical HSIL' on June 24.
Brief Summary: This is a single-arm, open label, multi-center clinical study to evaluate the safety, tolerability and immunogenicity HPV16 targeted mRNA therapeutic vaccine (NWRD09) in HPV16 related cervical high-grade squamous intraepithelial lesions (HSlL).
Study Start Date: June 12
Study Type: INTERVENTIONAL
Condition:
High-grade Squamous Intraepithelial Lesion (HSIL)
Intervention:
BIOLOGICAL: NWRD09 injection
NWRD09 administered by intramuscular injection
Recruitment Status: RECRUITING
Sponsor: Newish Biotech (Wuxi) Co., Ltd.
Published by HT Digital Content Services w...